|
Screening for disorder of haemostasis in the patient with RPL. |
||
| Parameters (unit of measurement) |
Results |
Normal range |
|
|
||
| Prothrombin time (INR) |
1.15 |
0.8–1.2 |
| Activated partial thromboplastin time (ratio) |
1.45 |
0.8–1.2 |
| Fibrinogen (mg/dL) |
275 |
220–420 |
| Protein C (%) |
93 |
60–125 |
| Protein S (%) |
92 |
60–125 |
| Antithrombin III (%) |
104 |
80–120 |
| Anticardiolipin Ab IgM (U/GPL) |
1.7 |
< 2.0 |
| Anticardiolipin Ab IgG (U/MPL) |
3.9 |
< 7.0 |
| β-2-GP I Ab |
Absent |
Absent |
| Lupus anticoagulant |
Absent |
Absent |
| Factor XII (%) |
65 |
80–120 |
| Factor XI (%) |
113 |
80–120 |
| Factor X (%) |
112 |
80–120 |
| Factor IX (%) |
99 |
80–120 |
| Factor VIII (%) |
88 |
65–155 |
| Factor V (%) |
110 |
80–120 |
| MTHFRC677T gene polymorphism |
Wild type |
Wild type |
| PTHRA20210 gene polymorphism |
Wild Type |
Wild type |
| FVL gene polymorphism |
Wild Type |
Wild type |
|
INR: international normalised ratio MTHFRC677T: methylene-tetra-hydrp-folate reductase C677T gene polymorphism PTHRA20210G: prothrombin A20210G gene polymorphism FVL: factor V Leiden gene polymorphism β-2-GP I Ab: Antibodies to β-2-glycoprotein I | ||
D'Uva et al. Journal of Translational Medicine 2005 3:43 doi:10.1186/1479-5876-3-43 |
||